NCT06427330View on ClinicalTrials.gov

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Acute Lymphoid Leukemia
Interventions
DRUG

Inotuzumab ozogamicin

"1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2"

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER